Kenvue on Thursday forecast that its annual profit would be flat year-over-year as the consumer health firm anticipates a ...

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

Kenvue Inc. (NYSE: KVUE), today announced the appointment of Amit Banati as the Company’s Chief Financial Officer, effective ...

(NYSE: KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our ...

Shares of Kenvue rose in premarket trading Thursday after the maker of Band-Aid, Tylenol, and Listerine reported ...

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

The stock's rise snapped a three-day losing streak.

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Discover Kenvue's Q1 2025 earnings insights—strategic growth, tariff mitigation, innovation focus, and supply chain resilience to drive performance this year.

Kenvue KVUE4.11%increase; green up pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSofya Tsinis - Head of Investor RelationsThibaut ...

May 8 (Reuters) - Kenvue (KVUE.N), opens new tab beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self-care products including cough and cold ...